Published in J Hum Genet on July 16, 2015
Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers. Trends Cardiovasc Med (2016) 0.75
Improving medical students' knowledge of genetic disease: a review of current and emerging pedagogical practices. Adv Med Educ Pract (2015) 0.75
Identification of Small Molecule Inhibitors of Human As(III) S-Adenosylmethionine Methyltransferase (AS3MT). Chem Res Toxicol (2015) 0.75
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med (2006) 23.83
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet (2005) 12.12
SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med (2008) 11.31
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med (2013) 8.21
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 7.39
A randomized trial of genotype-guided dosing of warfarin. N Engl J Med (2013) 7.18
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 6.12
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature (2004) 5.95
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA (2011) 5.93
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 5.59
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science (2008) 4.50
Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA (2004) 4.47
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet (2009) 4.32
A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med (2013) 4.27
CYP4F2 genetic variant alters required warfarin dose. Blood (2008) 4.23
Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther (2012) 4.05
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood (2006) 3.49
Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med (2010) 3.32
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol (1998) 3.13
The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol (2009) 3.10
Pitx2c and Nkx2-5 are required for the formation and identity of the pulmonary myocardium. Circ Res (2007) 3.00
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation (2002) 2.98
A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A (2006) 2.72
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet (2010) 2.72
Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) (2004) 2.68
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics (2006) 2.66
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics (1994) 2.55
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature (2013) 2.46
Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One (2010) 2.43
Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin Proc (2014) 2.07
Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation (1999) 2.01
Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Sci Transl Med (2012) 1.99
Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet (2008) 1.99
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J (2009) 1.92
Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current. Circulation (2014) 1.86
Pitx2 prevents susceptibility to atrial arrhythmias by inhibiting left-sided pacemaker specification. Proc Natl Acad Sci U S A (2010) 1.84
Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc (2013) 1.80
KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation (1997) 1.76
Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther (2014) 1.73
Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics (2012) 1.66
Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. J Am Coll Cardiol (2014) 1.65
Common genetic variants and response to atrial fibrillation ablation. Circ Arrhythm Electrophysiol (2015) 1.62
A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet (2011) 1.48
Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics (2007) 1.39
Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics (2011) 1.34
Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome. Circ Arrhythm Electrophysiol (2009) 1.33
Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation. J Am Coll Cardiol (2012) 1.27
Clopidogrel: a case for indication-specific pharmacogenetics. Clin Pharmacol Ther (2012) 1.20
A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenet Genomics (2008) 1.19
The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther (2012) 1.19
Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet (2011) 1.19
Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet Genomics (2008) 1.18
Pharmacogenomics: the genetics of variable drug responses. Circulation (2011) 1.10
Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet Genomics (2011) 1.09
Clopidogrel and the concept of high-risk pharmacokinetics. Circulation (2009) 1.06
Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion. Heart Rhythm (2013) 1.04
Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizes. PLoS One (2013) 1.04
Cardiovascular pharmacogenomics. Circ Res (2011) 1.03
Genetic risk factors for major bleeding in patients treated with warfarin in a community setting. Clin Pharmacol Ther (2014) 0.95
Increased persistent sodium current due to decreased PI3K signaling contributes to QT prolongation in the diabetic heart. Diabetes (2013) 0.91
Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels. Circ Res (2015) 0.88
Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenet Genomics (2010) 0.83
A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record. Thromb Haemost (2014) 0.83
Disclosing genetic risk for coronary heart disease: effects on perceived personal control and genetic counseling satisfaction. Clin Genet (2015) 0.82
Integrative analysis of proteomic and transcriptomic data for identification of pathways related to simvastatin-induced hepatotoxicity. Proteomics (2013) 0.82
Using systems approaches to address challenges for clinical implementation of pharmacogenomics. Wiley Interdiscip Rev Syst Biol Med (2013) 0.79
Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke. Pharmacogenet Genomics (2008) 0.79
Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. Br J Pharmacol (2014) 0.78
Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia. Pharmacogenet Genomics (2012) 0.77
Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction. Pharmacogenet Genomics (2010) 0.76